Anzeige
+++40 Mio. USD Staatsaufträge bis 2029, doch die Aktie notiert noch bei 0,67 CAD+++
Portfolio Tracker
Dein Depot in Echtzeit – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige
EQS-News

AssureTrace Appoints Graham Clark as Business Director and Chief Revenue Officer 10.11.2026, 09:15 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: AssureTrace / Key word(s): Personnel
AssureTrace Appoints Graham Clark as Business Director and Chief Revenue Officer

10.11.2026 / 09:15 CET/CEST
The issuer is solely responsible for the content of this announcement.


Clark joins the AssureTrace Board, bringing more than 23 years of international serialization experience.

DUBLIN, Nov. 10, 2026 /PRNewswire/ -- AssureTrace, the Irish company bringing second-generation serialization management to the pharmaceutical industry, has appointed Graham Clark as Business Director and Chief Revenue Officer (CRO). Clark also joins its Board of Directors.

Graham Clark, Business Director and Chief Revenue Officer (CRO) and Member of the Board of Directors at AssureTrace.

A co-founder of TraceLink, Clark has worked through the introduction of the EU Falsified Medicines Directive (FMD), the US Drug Supply Chain Security Act (DSCSA) and other international traceability programmes.

"The first generation of serialization was about getting systems implemented and meeting regulatory deadlines. Today, the challenge is how to run compliance reliably every day, across every market in which a company operates," said Clark.

"Whether a company runs a mature FMD system approaching renewal or manages serialization across many markets as a contract manufacturer, keeping that expertise in-house is hard to sustain. AssureTrace brings together a structured operating model, established technology and managed-service providers that pharmaceutical companies already know and trust, to turn regulatory requirements into dependable day-to-day operations."

"Technology delivery has moved from on-premise, to the cloud, to managed services, and the reason for choosing managed services has moved from cost, to pooled expertise, to flexibility and speed," Clark added. "When specialists run the routine, a new market, a new trading partner or a new standard becomes a change to a service, not a new internal project. We believe second-generation serialization, delivered as a managed service, is what will let our industry adopt new technology at the pace it is now arriving."

Focused on operational efficiency, AssureTrace's service-led model combines compliance operations delivered locally by qualified managed-service providers working to one AssureTrace operating standard, with European-engineered SoftGroup technology. Customers retain regulatory accountability and oversight. SoftGroup's platform has replaced first-generation systems at 40 companies.

"Graham's international experience and understanding of the pharmaceutical serialization landscape will be instrumental as we scale AssureTrace and its partner network across Europe and North America," said Venelin Dimitrov, Co-Founder and CEO of AssureTrace. "For more than two decades SoftGroup has built serialization technology trusted by 167 pharmaceutical customers in 43 markets, with 98% retention. AssureTrace builds on that foundation to address the ongoing operational demands of compliance through a service-led model."

About AssureTrace

Compliance, handled.

www.assuretrace.com 

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/assuretrace-appoints-graham-clark-as-business-director-and-chief-revenue-officer-302934590.html

rt.gif?NewsItemId=EN91268&Transmission_Id=202611100310PR_NEWS_EURO_ND__EN91268&DateId=20261110


10.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2431584  10.11.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer